{"id":746966,"date":"2023-04-12T08:15:46","date_gmt":"2023-04-12T12:15:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/"},"modified":"2023-04-12T08:15:46","modified_gmt":"2023-04-12T12:15:46","slug":"viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/","title":{"rendered":"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer"},"content":{"rendered":"
\n

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc.\u00a0(NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO). The Company also announced that Chief Operating Officer (COO) Carrie Melvin is no longer with the organization.<\/p>\n

Mr. Casciano, who most recently served as Chief Executive Officer (CEO) and member of the board of directors of Teal Bio, brings to Viridian more than two decades of sales, marketing, and commercial leadership experience in the biopharma industry.<\/p>\n

\u201cTony\u2019s arrival marks an important milestone in Viridian\u2019s growth and maturation,\u201d said Scott Myers, President and CEO of Viridian. \u201cWith the lead asset in our thyroid eye disease (TED) program in a Phase 3 trial and additional investigational therapies for TED following close behind, it is imperative that we focus on building a world class commercial operation. I\u2019m confident that under Tony\u2019s seasoned leadership, we\u2019ll be well positioned to do just that. I\u2019m thrilled to be working with him in this endeavor as we pursue our vision to become a fully integrated biopharmaceutical company.\u201d<\/p>\n

Prior to leading Teal Bio, Mr. Casciano spent four years at AMAG Pharmaceuticals, serving initially as Senior Vice President, Head of U.S. Sales and Marketing before ascending to Executive Vice President, COO\/CCO. During his time at AMAG, he was responsible for leading more than 300 staff across a range of functions, including commercial, market access, patient services, and alliance management.<\/p>\n

\u201cI\u2019m delighted to be joining Viridian at such a remarkable time for the organization,\u201d said Mr. Casciano. \u201cThroughout my career, I\u2019ve taken immense pride in assembling high-performing teams to help ensure that patients gain access to the therapies they need. It\u2019s incredibly exciting to think that Viridian is moving closer to delivering novel therapies to an underserved population, and I\u2019m honored to be able to play an important part in that process.\u201d<\/p>\n

Mr. Casciano began his career in industry in sales positions at Sanofi\/Genzyme, rising through that organization in roles of increasing responsibility. He completed his 16-year tenure there as Head of Marketing, General Medicines. He holds a B.S. from Bridgewater State University and has completed multiple executive education programs.<\/p>\n

\n About Viridian Therapeutics<\/strong>\n <\/p>\n

Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian\u2019s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.<\/p>\n

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company recently initiated its first global Phase 3 trial called \u2018THRIVE\u2019 to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also evaluating VRDN-001 in a Phase 2 proof-of-concept trial in patients with chronic TED. In addition to its intravenously administered VRDN-001 program, the Company is advancing two candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is developing multiple preclinical assets in autoimmune and rare diseases.<\/p>\n

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com<\/a>. Follow Viridian on LinkedIn<\/a> and twitter<\/a>.<\/p>\n

\n Contacts
<\/strong>
\n
Investors:
Louisa Stone, 508-808-2400
Manager, Investor Relations
IR@viridiantherapeutics.com<\/a><\/p>\n

Todd James, 617-272-4691
Senior Vice President, Corporate Affairs and Investor Relations
IR@viridiantherapeutics.com<\/a><\/p>\n

Media:
Matt Fearer, 617-272-4605
Vice President, Corporate Communications
Media@viridiantherapeutics.com<\/a><\/p>\n

Source:\u00a0Viridian Therapeutics, Inc.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc.\u00a0(NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO). The Company also announced that Chief Operating Officer (COO) Carrie Melvin is no longer with the organization. Mr. Casciano, who most recently served as Chief Executive Officer (CEO) and member of the board of directors of Teal Bio, brings to Viridian more than two decades of sales, marketing, and commercial leadership experience in the biopharma industry. \u201cTony\u2019s arrival marks an important milestone in Viridian\u2019s growth and maturation,\u201d said Scott Myers, President and CEO of Viridian. \u201cWith the … <\/p>\n

Continue reading “Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746966","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nViridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc.\u00a0(NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO). The Company also announced that Chief Operating Officer (COO) Carrie Melvin is no longer with the organization. Mr. Casciano, who most recently served as Chief Executive Officer (CEO) and member of the board of directors of Teal Bio, brings to Viridian more than two decades of sales, marketing, and commercial leadership experience in the biopharma industry. \u201cTony\u2019s arrival marks an important milestone in Viridian\u2019s growth and maturation,\u201d said Scott Myers, President and CEO of Viridian. \u201cWith the … Continue reading "Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-12T12:15:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer\",\"datePublished\":\"2023-04-12T12:15:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/\"},\"wordCount\":605,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/\",\"name\":\"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ==\",\"datePublished\":\"2023-04-12T12:15:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer - Market Newsdesk","og_description":"WALTHAM, Mass., April 12, 2023 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc.\u00a0(NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Tony Casciano to the role of Chief Commercial Officer (CCO). The Company also announced that Chief Operating Officer (COO) Carrie Melvin is no longer with the organization. Mr. Casciano, who most recently served as Chief Executive Officer (CEO) and member of the board of directors of Teal Bio, brings to Viridian more than two decades of sales, marketing, and commercial leadership experience in the biopharma industry. \u201cTony\u2019s arrival marks an important milestone in Viridian\u2019s growth and maturation,\u201d said Scott Myers, President and CEO of Viridian. \u201cWith the … Continue reading \"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-12T12:15:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer","datePublished":"2023-04-12T12:15:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/"},"wordCount":605,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/","name":"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ==","datePublished":"2023-04-12T12:15:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNjAyNyM1NTIxMjQ4IzUwMDEwNDAzNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/viridian-therapeutics-appoints-tony-casciano-as-chief-commercial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746966","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746966"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746966\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746966"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746966"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746966"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}